Neogen (NEOG) Q4 FY26 earnings call: guidance and Q&A

Why is the FY27 EBITDA guide, excluding Genomics, below Street expectations, and what are the underlying assumptions for Food Safety vs. Animal Safety growth?

Management clarified that the EBITDA guide is roughly flat year-over-year due to increased investments, but is above Street consensus when Genomics is included. They aim to rebuild credibility. While not providing specific segment guidance, they indicated Food Safety is expected to grow faster than Animal Safety, with an overall core growth of approximately 3% for FY27.

“I think you're the only analyst that didn't include genomics for the full year in your number for next year. All the other analysts did. And so when you look at the actual consensus, if you adjust it for that, it would increase it slightly, but we're still well above where consensus was for the year.”

asked by Subhalaxmi Nambi · answered by R. Riggsbee

Is the Q1 EBITDA guide impacted by new investments, and is the commercial reorg a catch-up or an opportunity to get ahead of competitors?

Management stated Q1 is seasonally weaker, and while investments are starting, seasonality is the primary driver of sequential EBITDA. They affirmed real operating leverage. The commercial reorg is seen as both a catch-up in some areas and an opportunity to lead the market by realigning resources, investing in e-commerce, focusing on strategic accounts, and shifting to solution-based selling.

“I would say that a lot of what we're talking about here is -- and the way we think about it is we're going to be the leader in this space. And so what are the investments and the capabilities that we need to have in place in order to really drive that and not concern ourselves so much with where the competition is, but we set the market.”

asked by David Westenberg · answered by R. Riggsbee

What is the P&L impact of the Petrifilm product transfer over the next year, including D&A, labor costs, and margin changes?

Management confirmed the Petrifilm transition is on track, with the first SKU validation in August being a major de-risking event. They expect less duplicative costs over time, with the full 200-300 basis points of gross margin expansion from the new line primarily benefiting FY28, as FY27 will be focused on completing the multi-quarter transition.

“I would expect that we would start to see that benefit coming online in the following fiscal year. So probably because it will take us through the course of the year to complete the transition, and then we would start to see the benefit as we optimize through FY '28.”

asked by Bob Labick · answered by R. Riggsbee

Can you elaborate on the significant increase in R&D investment to 5% of sales and the specific areas of focus?

Management stated the R&D increase (50% in FY27) is crucial for organic innovation, which has been historically underinvested. Focus areas include building an early innovation discovery engine for Petrifilm, pathogens, general sanitation, digital connectivity, and instrumentation. They highlighted a pilot line investment for Petrifilm to enable two new SKUs per year and five simultaneous innovation projects, with long-term revenue contributions expected from FY29.

“We plan to increase R&D investment by about 50% next year and intend to continue scaling R&D at an accelerated pace with a long-term objective of approaching 5% of revenue.”

asked by Bob Labick · answered by Mikhael Nassif